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Background: Mutations in KRAS, BRAF and PIK3CA are the most common somatic alterations found in the
colorectal cancer (CRC) patients from Western countries; but their prevalence and prognostic value have not been
adequately assessed in Asian patients. The aim of this study was to determine the mutation frequencies of these
genes in Chinese CRC patients and to investigate their impact on prognosis.
Methods: The sequences of exon 2 of KRAS, exon 15 of BRAF and exons 9 and 20 of PIK3CA were evaluated by PCR
and direct sequencing using DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues from primary CRC
tumors of 214 patients (colon/rectum: 126/88).
Results: KRAS, BRAF and PIK3CA mutations were identified in 44.9% (96/214), 4.2% (9/214) and 12.3% (26/212) CRCs,
respectively. The most frequent mutations in KRAS, BRAF and PIK3CA were G12D, V600E and H1047R, respectively. All
BRAF and 80.8% PIK3CA mutations were from colon cancer patients. BRAF V600E was associated with advanced TNM
(P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2,
P = 0.004) in colon cancer patients. Compared with KRAS wt/BRAF wt CRC patients (N = 109), those with KRAS codon
13 mutations (N = 25) had significantly worse OS (P = 0.016; multivariate HR = 2.7, P = 0.011), whereas KRAS codon
12-mutated cases were not significantly associated with survival. Among the three most common KRAS mutations,
G13D (N = 23) showed significant association with poor OS (P = 0.024; multivariate HR = 2.6, P = 0.016) compared
with KRAS wt/BRAF wt patients.
Conclusion: Our findings indicate that PI3K/RAS-RAF signaling pathway genes are frequently mutated in Chinese
CRC patients, but have different characteristics than found in Western patients. BRAF V600E is an independent
prognostic factor for Chinese patients. Our finding that KRAS codon 13 mutations (in particular G13D) are associated
with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far. Our data emphasizes the
importance of prospective evaluation of molecular features in CRC patients, because a single mutation type may
represent a distinct biologic effect and clinical implication.
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Colorectal cancer (CRC) is one of the most common ma-
lignancies both in Western and in Asian countries [1]. In
recent years, the morbidity and mortality of CRC have in-
creased rapidly in the Chinese population, so that CRC
has become the third leading cause of cancer deaths in
China [2]. CRC arises through a multistep carcinogenic
process with an accumulation of epigenetic and genetic
alterations. Activation of two main EGFR-dependent
signaling pathways, the RAS-RAF and the PI3K-PTEN-
AKT pathways through mutations was considered to be
one of the most common mechanisms involved in colo-
rectal carcinogenesis. Numerous studies have indeed
observed that KRAS, BRAF and PIK3CA mutations are
commonly present in CRC, with frequencies of 30-50%,
10-15% and 10-20%, respectively. KRAS mutations occur
90% in exon 2 at codons 12 and 13. BRAF mutations are
mostly located at codon 600 with a conversion of valine
to glutamic acid (V600E) [3].
Although the predictive role of KRAS mutations, and
more recently also BRAF mutations to recognize resis-
tance to anti-EGFR therapy in advanced CRC patients
has been accepted widely [3-7], the prognostic role of
KRAS mutations in CRCs for survival is still controversial
[8-12]. For the BRAF V600E mutation, many studies have
shown its association with a poor clinical outcome
[9,10,12,13]. Given that mutations in KRAS and BRAF
are mutually exclusive, BRAF mutations may have poten-
tial confounding effect when estimating the prognostic
value of KRAS mutations. It was recognized only recently
in the studies of Yokota (N = 229) [13] and Imamura
(N = 1261) [14] that the prognostic significance of KRAS
mutation can be better examined in BRAF wild-type
CRCs, because almost all BRAF mutant patients are
KRAS wild-type.
Other studies have shown that different KRAS muta-
tions in CRCs may have different biological characteristics
and may consequently have variable effects in patients.
Firstly, an in vitro study showed that KRAS codon 13 mu-
tations (mainly the p.G13D mutation) exhibited weaker
transforming activity than codon 12 mutations [15]. Sec-
ondly, several clinical studies compared the prognostic
roles of KRAS codon 12 mutations with those of codon
13, but did not yet reach consensus because of the limited
results, though most studies agreed that KRAS mutations
in codon 13 confered a poorer prognosis and outcome for
patients under standard chemotherapy [13,14,16-18].
Thirdly, a recent retrospective study of De Rook et al.
analyzed the association between KRAS mutations in
codon 13 (G13D) versus codon 12 evaluating response
and survival in patients with chemotherapy refractory
treated with cetuximab, and showed that patients with the
KRAS G13D mutation could benefit from cetuximab
therapy, whereas those with a KRAS codon 12 mutationwere likely to be resistant to cetuximab [19]. An increa-
sing number of sometimes contradictory studies showed
that patients with KRAS mutations in codon 13 could
have a poorer outcome, but would significantly benefit
clinically from an anti-EGFR therapy [20]. Apparently, the
real mechanism by which different KRAS mutations affect
tumor biology and lead to different outcomes needs to be
further elucidated.
PIK3CA mutations cluster 90% in hotspots of exons 9
and 20, and affect the functionally important helical and
kinase domains. PIK3CA mutations are likely to be asso-
ciated with a poor prognosis [21,22] and clinical resist-
ance to anti-EGFR targeted therapy [23].
Most of the studies that investigated the frequencies
and prognostic values of KRAS, BRAF, PIK3CA muta-
tions, and in particular, the efficacies of targeted therap-
ies were performed in Western countries. There is not
yet agreement on mutation frequencies in Chinese CRC
patients, especially for BRAF and PIK3CA, because the
frequencies of such mutations were reported differently
in the few data published (Table 1). Furthermore, little is
known about their prognostic value in Chinese CRC pa-
tients, since few studies had follow-up data. In our study,
we aimed to identify the mutation frequencies of KRAS,
BRAF and PIK3CA in primary tumors of a cohort of 214
Chinese CRC patients, and to assess their correlations
with the clinicopathological characteristics. In addition,
follow-up data were collected from all patients to deter-
mine their potential prognostic roles in survival.
Methods
Patients and tumor samples
Among the 436 consecutive patients diagnosed with colo-
rectal cancer at Zhongda Hospital Affiliated to Southeast
University (Nanjing, China) from 2007 to 2012, 35 were
excluded because no surgery was performed. An add-
itional 140 patients were excluded, as they were lost
during follow-up period. Among the 261 patients eligible
for the genetic testing, 38 patients were excluded because
no tissue blocks were available. An extra 9 patients were
excluded from the remaining 223 patients because of poor
DNA quality. At last 214 patients were included in our
study (Figure 1). There was no difference in the major
clinicopathological characteristics between the included
and excluded patients (see Additional file 1). All of these
patients were histologically confirmed colorectal cancer by
two experienced pathologists. None of the patients re-
ceived any adjuvant therapy before resection. The median
follow-up time of surviving patients was 34 months. The
patients’ demographic and clinicopathological data are
presented in Table 2. The collection of materials and
patient data was approved by the Institutional Ethics
Committee of Zhongda Hospital and written informed
consent was obtained from the participants. The study
Table 1 Studies on mutation status of KRAS, BRAF and PIK3CA in Chinese CRC patients
Reference (year) No. of
patients
Method Mutation frequencies Region Prognostic value
[2] Gao J., et al.
(2011)
273 Direct sequencing KRAS (38.5%); BRAF (5.1%) Chinese
[24] Li H.T., et al.
(2011)
200 Pyrosequencing KRAS (31.5%); BRAF (7.0%);
PIK3CA (12.5%)
Chinese KRAS and PIK3CA bi-mutations were more
likely to develop liver metastases.
[25] Shen H., et al.
(2011)
118 Pyrosequencing KRAS (34.7%); BRAF (1.7%) Chinese
[26] Liou J.M., et al.
(2011)
314 Direct sequencing KRAS (20.7%); BRAF (3.8%) Taiwan BRAF mutation was associated with worse
overall survival.
[27] Mao C., et al.
(2012)
69 Direct sequencing KRAS (43.9%); BRAF (25.4%);
PIK3CA (8.2%)
Chinese
[28] Hsieh L.L., et al.
(2012)
182 Direct sequencing &
HRM
KRAS (33.5%); BRAF (1.1%);
PIK3CA (7.1%)
Taiwan
[29] Zhu Y.F., et al.
(2012)
60 Direct sequencing PIK3CA (21.6%) Chinese High PI3K expression was associated
with CRC metastases.
[30] Li Z., et al.
(2012)
78 Direct sequencing KRAS (33.3%) Chinese KRAS mutations were associated with poor
survival and liver metastasis.
[31] Shen Y., et al.
(2013)
676 Direct sequencing KRAS (35.9%); BRAF (6.96%);
PIK3CA (9.9%)
Chinese
[32] Pu X., et al. (2013) 115 Direct sequencing KRAS (32.2%); BRAF (3.5%) Chinese
[33] Wang J., et al.
(2013)
574 Direct sequencing KRAS (34.2%) Chinese
[34] Chang Y.S., et al.
(2013)
165 HRM KRAS (36.97%); BRAF (4.24%) Taiwan KRAS mutation was associated with
poor survival.
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and the regulations set by Chinese law for the use of hu-
man material for research.
DNA extraction and mutation analysis
Genomic DNA was extracted from 5 sections of 10 μm
thickness of macro-dissected formalin-fixed paraffin-
embedded (FFPE) tumor samples, containing at least 50%
tumor epithelium, as determined by an experiencedFigure 1 Selection of study population.pathologist in H&E-stained paraffin sections. The QIAmp
DNA Mini Kits (Qiagen GmbH, Hilden, Germany) was
used according to the manufacturer’s instructions. For
each sample, exons 9 and 20 of PIK3CA, exon 2 of KRAS,
and exon 15 of BRAF were amplified by PCR. The pre-
sence of mutations was detected by direct sequencing at
Beijing Genomic Institute (BGI, ABI 3730xL Genetic
analyzer, Shenzhen, China) using the BigDye Terminator
Cycle Sequencing kit (Applied Biosystems). For all PCR
products with sequence variants, both forward and reverse
sequence reactions were repeated for confirmation.
Primers used for the amplification are listed in Table 3.
Statistical analysis
All statistical analyses were carried out with SPSS statis-
tical software (version 18.0 for Windows, SPSS, Inc.).
Data were analyzed with the Mann–Whitney test to
compare quantitative and ordered variables and with
Student's t test to compare normally distributed data be-
tween two groups. χ2 test and Fisher's exact test were
used to compare proportions. Survival analyses were
done using the Kaplan-Meier (KM) method with time of
surgery as entry date. Overall survival (OS) was defined
as the period from the date of surgery until death from
any cause or last follow-up. Log rank testing was used
for comparison of groups.
To identify factors associated with OS, we evaluated the
following clinicopathological variables in a univariate Cox
Table 2 Clinicopathological characteristics according to PI3K/RAS-RAF pathway gene mutation status in 214 (212) colorectal cancer patients
KRAS exon 2 BRAF exon 15 PIK3CA exon 9&20* PI3K/RAS-RAF pathway*
No. patients (214/212) No (%) Yes (%) P No (%) Yes (%) P No (%) Yes (%) P No (%) Yes (%) P
Sex male 127 (126) 73 (61.9) 54 (56.3) 0.406a 122 (59.5) 5 (55.6) 1.000b 109 (58.6) 17 (65.4) 0.509a 60 (61.2) 66 (57.9) 0.623a
female 87 (86) 45 (38.1) 42 (43.8) 83 (40.5) 4 (44.4) 77 (41.4) 9 (34.6) 38 (38.8) 48 (42.1)
Age 68.0 67.1 69.1 0.286d 68.0 66.9 0.801d 68.7 64.6 0.133d 67.8 68.4 0.728d
Location colon 126 (124) 73 (61.9) 53 (55.2) 0.325a 117 (57.1) 9 (100.0) 0.011b 103 (55.4) 21 (80.8) 0.014a 54 (55.1) 70 (61.4) 0.353a
rectum 88 (88) 45 (38.1) 43 (44.8) 88 (42.9) 0 (0) 83 (44.6) 5 (19.2) 44 (44.9) 44 (38.6)
Differentiation well 29 (29) 19 (16.1) 10 (10.4) 0.912c 28 (13.7) 1 (11.1) 0.131c 22 (11.8) 7 (26.9) 0.215c 15 (15.3) 14 (12.3) 0.521c
moderate 163 (161) 83 (70.3) 80 (83.3) 159 (77.6) 4 (44.4) 145 (78.0) 16 (61.5) 73 (74.5) 88 (77.2)
poor 7 (7) 7 (5.9) 0 (0) 5 (2.4) 2 (22.2) 5 (2.7) 2 (7.7) 3 (3.1) 4 (3.5)
missing 15 (15) 9 (7.6) 6 (6.3) 13 (6.3) 2 (22.2) 14 (7.5) 1 (3.8) 7 (7.1) 8 (7.0)
Tumor diameter <5 cm 103 (102) 53 (44.9) 50 (52.1) 0.254c 101 (49.3) 2 (22.2) 0.171b 93 (50.0) 9 (34.6) 0.172a 46 (46.9) 56 (49.1) 0.710a
> = 5 cm 108 (107) 64 (54.2) 44 (45.8) 101 (49.3) 7 (77.8) 91 (48.9) 16 (61.5) 51 (52.0) 56 (49.150.0)
missing 3 (3) 1 (0.8) 2 (2.1) 3 (1.5) 0 (0) 2 (1.1) 1 (3.8) 1 (1.0) 2 (1.8)
TNM-stage I 32 (32) 15 (12.7) 17 (17.7) 0.828c 32 (15.6) 0 (0) 0.007c 26 (14.0) 6 (23.1) 0.433c 13 (13.3) 19 (16.7) 0.231c
II 78 (77) 50 (42.4) 28 (29.2) 76 (37.1) 2 (22.2) 69 (37.1) 8 (30.8) 44 (44.9) 33 (28.9)
III 82 (81) 38 (32.2) 44 (45.8) 79 (38.5) 3 (33.3) 70 (37.6) 11 (42.3) 31 (31.6) 50 (43.9)
IV 19 (19) 13 (11.0) 6 (6.3) 15 (7.3) 4 (44,4) 18 (9.7) 1 (3.8) 8 (8.2) 11 (9.6)
missing 3 (3) 2 (1.7) 1 (1.0) 3 (1.5) 0 (0) 3 (1.6) 0 (0) 2 (2.0) 1 (0.9)
T T1 5 (5) 4 (3.4) 1 (1.0) 0.236c 5 (2.4) 0 (0) 0.057c 5 (2.7) 0 (0) 0.808c 4 (4.1) 1 (0.9) 0.724c
T2 35 (35) 15 (12.7) 20 (20.8) 35 (17.1) 0 (0) 29 (15.6) 6 (23.1) 13 (13.3) 22 (19.3)
T3 167 (166) 93 (78.8) 74 (77.1) 159 (77.6) 8 (88.9) 147 (79.0) 19 (73.1) 77 (78.6) 89 (78.1)
T4 5 (4) 4 (3.4) 1 (1.0) 4 (2.0) 1 (11.1) 3 (1.6) 1 (3.8) 2 (2.0) 2 (1.8)
missing 2 (2) 2 (1.7) 0 (0) 2 (1.0) 0 (0) 2 (1.1) 0 (0) 2 (2.0) 0 (0)
N N(−) 115 (114) 70 (59.3) 45 (46.9) 0.050a 113 (55.1) 2 (22.2) 0.083b 99 (53.2) 15 (57.7) 0.710a 61 (62.2) 53 (46.5) 0.013a
N(+) 97 (96) 46 (39.0) 51 (53.1) 90 (43.9) 7 (77.8) 85 (45.7) 11 (42.3) 35 (35.7) 61 (53.5)
missing 2 (2) 2 (1.7) 0 (0) 2 (1.0) 0 (0) 2 (1.1) 0 (0) 2 (2.0) 0 (0)
Metastases M(−) 163 (161) 88 (74.6) 75 (78.1) 0.367a 159 (77.6) 4 (44.4) 0.037b 144 (77.4) 17 (65.4) 1.808a 77 (78.6) 84 (73.7) 0.689a
M(+) 51 (51) 30 (25.4) 21 (21.9) 46 (22.4) 5 (55.6) 42 (22.6) 9 (34.6) 21 (21.4) 30 (26.3)
Synchronous metastases M(−) 193 (191) 104 (88.1) 89 (92.7) 0.224a 188 (91.7) 5 (55.6) 0.004b 166 (89.2) 25 (96.2) 0.479b 89 (90.8) 102 (89.5) 0.708a
M(+) 19 (19) 13 (11.0) 6 (6.3) 15 (7.3) 4 (44.4) 18 (9.7) 1 (3.8) 8 (8.2) 11 (9.6)
missing 2 (2) 1 (0.8) 1 (1.0) 2 (1.0) 0 (0) 2 (1.1) 0 (0) 1 (1.0) 1 (1.0)
Metachronous metastases M(−) 176 (174) 95 (80.5) 81 (84.4) 0.462a 171 (83.4) 5 (55.6) 0.055b 156 (83.9) 18 (69.2) 0.097b 82 (83.7) 92 (80.7) 0.574a
M(+) 38 (38) 23 (19.5) 15 (15.6) 34 (16.6) 4 (44.4) 30 (16.1) 8 (30.8) 16 (16.3) 22 (19.3)


















Table 3 The primers used in PCR amplification and
sequencing
Genes Primers (sequence 5’– > 3’)
KRAS
Exon 2 F: TTAACCTTATGTGTGACATGTTCTAA
R: ATCAAAGAATGGTCCTGCAC
BRAF
Exon 15 F: CTTTACTTACTACACCTCAG
R: TAACTCAGCAGCATCTCAGG
PIK3CA
Exon 9 F: AGTAACAGACTAGCTAGAGACAAT
R: CATGCTGAGATCAGCCAAAT
Exon 20 F: ATGATGCTTGGCTCTGGAAT
R: TGTGGAATCCAGAGTGAGCTT
Table 4 KRAS, BRAF and PIK3CA mutations identified in
214 colorectal cancer patients
Nucleotide Amino acid Case (total) %
KRAS 96 (214) 44.9
exon 2 34G > A G12S 2
34G > C G12R 1
34G > T G12C 5
35G > A G12D 34
35G > C G12A 8
35G > T G12V 20
35G > T & 35G > A G12V & G12D 1
37G > T G13C 2
38G > A G13D 23
BRAF 9 (214) 4.2
exon 15 1799 T > A V600E 8
1801A > G K601E 1
PIK3CA 26 (212)* 12.3
exon 9 12 5.7
1624G > A E542K 1
1633G > A E545K 7
1634A > C E545A 1
1636C > A Q546K 2
1637A > G Q546R 1
exon 20 14 6.6
3062A > T Y1021F 2
3139C > T H1047Y 1
3140A > G H1047R 8
3140A > T H1047L 1
3145G > C G1049R 1
3155C > A T1052K 1
*DNA of 2 samples was not available for PIK3CA exon 20.
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tumor location (colon vs rectum), tumor differentiation
grade, tumor diameter (<5 cm vs ≥5 cm), number of
lymph nodes examined (<12 vs ≥12), TNM stage, KRAS
status (mutant vs wild-type (wt)), BRAF status (mutant
vs wt) and PIK3CA status (mutant vs wt). All variables
associated with OS with P < 0.1 in the univariate analysis
were entered into a Cox multivariate regression model
with backward elimination. A two-sided P value of
≤0.05 was considered statistically significant.
Results
Frequency and distribution of KRAS, BRAF and PIK3CA
mutations
KRAS mutation status in exon 2 was detected in 96 out
of 214 (44.9%) tumor samples, of which 70 (32.7%) had
a single mutation and one had two mutations in codon
12, and 25 (11.7%) had a single mutation in codon 13.
The most frequent mutation was 35G > A (G12D), which
represented 35.4% of all KRAS mutations, followed by
38G > A (G13D, 24.0%). BRAF mutations in exon 15
were found in 9 out of 214 (4.2%) tumor samples. Only
one case was 1801A > G (K601E), whereas the rest were
1799 T > A (V600E) mutations. PIK3CA mutations were
found in 26 out of 212 patients (12.3%), with 12 cases in
exon 9 (5.7%) and 14 cases in exon 20 (6.6%). The most
frequently detected mutations were 1633G > A (E545K)
in exon 9 and 3140A > G (H1047R) in exon 20 among a
total of 11 variants. Mutations are summarized in
Table 4. The distribution of the mutations in 212 sam-
ples is shown in Figure 2. In total, 114 cases (53.8%) had
a mutation in at least one of the three genes, with 97 pa-
tients (45.8%) having a mutation in a single gene and 17
patients (8.0%) in two genes. 16 cases had concomitant
occurrence of KRAS and PIK3CA mutations, but this as-
sociation was not statistically significant (P = 0.075).
Only one patient had a BRAF and a PIK3CA mutationsimultaneously. Mutations in KRAS and BRAF were not
observed in the same tumor (P = 0.005), which is con-
sistent with previous studies stating that they were mu-
tually exclusive [35].
PI3K/RAS-RAF pathway mutations and clinicopathological
characteristics
We did not find any significant associations between
KRAS mutations and patients’ clinicopathological charac-
teristics, except that KRAS mutations were associated
with more lymph node involvement (53.1% vs 46.9%,
P = 0.050). Data are shown in Table 2. Mutations in BRAF
or PIK3CA showed a significant correlation with tumor
location. All mutations in BRAF were from colon cancer
patients and almost all were localized in the proximal
colon (8/9). Likewise, most mutations in PIK3CA were
from colon cancer patients (21/26, P = 0.014). Compared
Table 5 Clinicopathological characteristics according to
BRAF V600E mutation status in 126 colon cancer patients
BRAF codon 600 mutation
No (%) Yes (%) P
Sex male 71 (60.2) 5 (62.5) 1.000b
female 47 (39.8) 3 (37.5)
Age 69.4 65.4 0.664d
Differentiation well 15 (12.7) 1 (12.5) 0.192c
moderate 91 (77.1) 3 (37.5)
poor 5 (4.2) 2 (25.0)
missing 7 (5.9) 2 (25.0)
Tumor diameter <5 cm 49 (41.5) 2 (25.0) 0.469b
> = 5 cm 67 (56.8) 6 (75.0)
missing 2 (1.7) 0 (0)
TNM-stage I 9 (7.6) 0 (0) 0.014c
II 50 (42.4) 2 (25.0)
III 49 (42.4) 2 (25.0)
IV 7 (5.9) 4 (50.0)
missing 2 (1.7) 0 (0)
T T1 0 (0) 0 (0) 0.106c
T2 9 (7.6) 0 (0)
T3 105 (89.0) 7 (87.5)
T4 2 (1.7) 1 (12.5)
missing 2 (1.7) 0 (0)
N N(−) 62 (52.5) 2 (25.0) 0.157b
N(+) 55 (46.6) 6 (75.0)
missing 1 (0.8) 0 (0)
Metastases M(−) 91 (77.1) 3 (37.5) 0.025b
M(+) 27 (22.9) 5 (62.5)
Synchronous metastases M(−) 110 (93.2) 4 (50.0) 0.002b
M(+) 7 (5.9) 4 (50.0)
missing 1 (0.8) 0 (0)
Metachronous metastases M(−) 96 (81.4) 4 (50.0) 0.056b
M(+) 22 (18.6) 4 (50.0)










Figure 2 The distribution of mutations is illustrated in a pie
chart of 212 colorectal cancer samples.
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who harbored at least one mutation in any of the three
genes were not different in any of the listed features ex-
cept lymph-node involvement when admitted (53.5% vs
35.7%, P = 0.013). There was no significant difference in
listed features between those carrying two gene muta-
tions and the wild-type patients (data not shown).
We further analyzed the impact of BRAF mutation in
the 126 colon-cancer patients. Among the 9 patients with
a BRAF mutation, 8 were V600E and 1 was K601E. As
mutation in codon 601 does not have a clear biological
function, we only took the V600E mutation into further
analysis (Table 5). The V600E mutation was correlated
with significantly higher TNM stage (P = 0.014). Further-
more, patients with this BRAF mutation had a >2.5-fold
higher risk for distant metastases than patients without
this mutation (62.5% vs 22.9%, P = 0.025). The risk for
synchronous metastases was >8-fold higher in patients
with than without this BRAF mutation (50.0% vs 5.9%,
P = 0.002). Notably, 3 out of 8 patients with the V600E
mutation developed both synchronous and metachro-
nous metastases.
Prognostic value of BRAF and KARS codon 13 mutations
In a KM analysis of the BRAF V600E mutation in 126
colon patients, V600E was strongly associated with a
poorer OS (log-rank P < 0.001; 3-year OS: 16.7% in the
BRAF V600E mutant vs 73.2% in the BRAF wild-type (wt);
Figure 3A). No differences were found between patients
with and without KRAS mutations (log-rank P = 0.133;
3-year OS: 64.6% in the KRAS mutant vs 72.4% in the
KRAS wt; Figure 3B) in the survival analysis. Similarly, no
differences were found for PIK3CA mutations or at least
one mutation in any of the three genes (data not shown).
However, several recent studies suggested to exclude theconfounding effect of BRAF mutation from KRAS wt
patients when evaluating the prognostic value of KRAS, as
BRAF mutation is associated with a poorer prognosis
[9,13,14]. We then selected BRAF wt cases only and com-
pared KRAS-mutants/BRAF wt cases with KRAS wt/BRAF
wt cases to assess the prognostic value of KRAS muta-
tions. A total of 205 cases (214 cases - 9 BRAF mutants)
remained in the analysis (Figure 4) with 52 death events.
Intriguingly, KRAS mutations showed its prognostic value
when BRAF mutations were excluded in the KM analysis
(log-rank P = 0.035; 3-year OS: 64.6% in KRAS mutants/





Figure 3 Kaplan-Meier curves. Panel A shows OS according to BRAF V600E mutation status in 126 colon cancer patients. Panel B shows OS
according to KRAS mutation status in 214 colorectal cancer patients. Panels C, D and E show OS according to KRAS, KRAS codon 13 and KRAS
c.38G > A (G13D) mutation status in 205 BRAF wild-type colorectal cancer patients, respectively.
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Figure 4 Flow chart of mutation detection in BRAF exon 15 and
KRAS exon 2 at codon 12 and 13.
Table 6 Analysis of OS in 126 colon cancer patients by
Cox regression analysis
Variables Univariate analysis Multivariate analysis






Male 3.0 (1.3-7.0) 3.3 (1.3-7.8)
Differentiation 0.160
well 1.0
moderate 0.5 (0.2-1.1) 0.089






> = 5 cm 1.7 (0.8-3.5)
TNM-stage <0.001 0.017
I 1.0 1.0
II 1.4 (0.2-10.8) 0.749 1.3 (0.2-9.9)
III 1.8 (0.2-13.9) 0.568 2.1 (0.3-15.9)




BRAF V600E status <0.001 0.004
wt 1.0 1.0




P-values ≤ 0.05 are in bold.
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KRAS mutations. Interestingly, patients with a KRAS
codon 13 mutation experienced a significant decrease in
OS in KM analysis compared with patients with a KRAS
wt/BRAF wt genotype (log-rank P = 0.016; 3-year OS:
53.4% in KRAS codon 13 mutants/BRAF wt vs 76.3% in
KRAS wt/BRAF wt; Figure 3D), while KRAS codon 12 mu-
tations did not show this effect. Among the 3 most com-
mon KRAS codon 12 and 13 mutations analyzed, c.38G >
A (p.G13D; N = 23) was significantly associated with
worse OS compared with KRAS wt/BRAF wt (log-rank
P = 0.024; 3-year OS: 55.8% in KRAS c.38G >A mutants/
BRAF wt vs 76.3% in KRAS wt/BRAF wt; Figure 3E).
Univariate and multivariate analysis of outcome
predictors
To correct for significant prognostic factors, variables
including age, sex, differentiation grade, tumor dia-
meter, number of lymph nodes examined, TNM stage
and KRAS/BRAF/PIK3CA genotype were first exam-
ined in colon cancer patients with the univariate Cox
regression model (Table 6). Besides sex (P = 0.009) and
TNM stage (P ≤ 0.000), BRAF V600E mutation showed
a significant association with a higher risk of overall
mortality (hazard ratio (HR), 5.1; 95% confidence inter-
val (CI), 2.1-12.4; P ≤ 0.001). The independent prog-
nostic value of the BRAF V600E mutation was further
tested in multivariate analysis with backward stepwise
elimination, including the following variables: sex,
TNM stage and BRAF V600E mutation. No significant
interactions were observed between the variables. The
BRAF V600E mutation remained as an independent
predictor for poor prognosis in patients with colon can-
cer (HR, 4.2; 95% CI, 1.6-11.0; P = 0.004) (Table 6). Com-
pared with the KRAS wt/BRAF wt cases, those with a
KRAS codon 13 mutation experienced a significant de-
crease in OS in the Cox regression analysis (univariate:
HR, 2.5, 95% CI, 1.2-5.2; P = 0.019; multivariate: HR, 2.7,
95% CI, 1.3-5.7; P = 0.011; Table 7). In contrast, patientswith KRAS codon 12 mutations did not experience a sig-
nificant decrease in survival. Among the 3 most common
KRAS codon 12 and 13 mutations, c.38G > A (G13D, N
= 23) was associated with significantly lower OS com-
pared with the KRAS wt/BRAF wt patients (univariate
HR, 2.4, 95% CI, 1.1-5.3; P = 0.026; multivariate HR, 2.6,
95% CI, 1.2-5.8; P = 0.016; Table 8).
Discussion
In this study, we determined mutation frequencies of
KRAS, BRAF and PIK3CA in 214 Chinese CRC patients
with resectable tumors and examined the correla-
tions between their genotypes and clinicopathological
Table 7 Analysis of OS according to KRAS mutation status in 205 BRAF wt colorectal cancer patients by cox regression
analysis
Univariate analysis Multivariate analysis
KRAS BRAF Total N No. of events HR (95% CI) P HR (95% CI) P
wt wt 109 22 1.0 1.0
All codon 12 mutants wt 71 20 1.6 (0.9-2.9) 0.139 1.4 (0.8-2.6) 0.247
All codon 13 mutants wt 25 10 2.5 (1.2-5.2) 0.019 2.7 (1.3-5.7) 0.011
NOTE: We tested KRAS codon 12 and 13 mutations among BRAF wild type cases.
The multivariate Cox regression model initially included age, sex, tumor location, tumor differentiation, tumor diameter, number of lymph nodes examined, TNM
stage, KRAS and PIK3CA status. A backward stepwise elimination with a threshold of P = 0.1 was used to select variables in the final model. TNM stage and KRAS
status were finally entered the multivariate analysis. P-values ≤ 0.05 are in bold.
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mutations were related to tumor site. In addition, we
clarified the prognostic values of BRAF V600E mutation
and KRAS mutations in codon 13. To the best of our
knowledge, we assessed for the first time the impact of
KRAS mutations, including distinguished mutation sub-
types, on prognosis in Chinese CRC patients when the
confounding effect of a BRAF mutation was controlled.
Comparing our results with the studies from Western
countries, differences in mutation distribution and fre-
quency were observed. We identified a frequency of ~45%
for a KRAS mutation, which is in the same range as found
in earlier studies of Chinese and Western CRC patients
[3,27]. The distribution of KRASmutations in the Western
population showed that G12D was the most frequent mu-
tation subtype in codon 12, followed by G12V/C/S/A/R or
G12V/S/C/A/R [27,36]. In contrast, the corresponding
order of KRAS codon 12 mutation frequency in our data
was G12D/V/A/C/S/R, as was found in another study of
Chinese CRC patients [31]. For codon 13, the order of
two mutation subtypes (38G >A and 37G > T) was not
different from that found by others. The BRAF mutation
frequency in CRC patients from Western countries is 10-
15% [37-39]. In our study, the BRAF mutation frequency
was ~4%, that is, in the same range as in Japanese and
other Chinese reports from different regions including
Taiwan (1-7%) [13,24,28,31]. This finding suggests that the
BRAF mutation frequency in Asian CRC patients is lower
than in Western patients.
The PIK3CA gene encodes the P110 catalytic subunit
of PI3K that regulates the pathway. In agreement withTable 8 Analysis of OS according to the 3 most common KRA
cancer patients by cox regression analysis
KRAS BRAF Total N No. of events
wt wt 109 22
c.38G > A wt 23 9
c.35G > A wt 34 9
c.35G > T wt 20 5
NOTE: The multivariate cox regression model included the same set of covariates seearlier studies, the PIK3CA mutation frequency was
~12% in our samples and could co-occur with KRAS or
BRAF mutations [21,37,40]. And, in the 17 cases with
concomitant mutations, 16 of them had PIK3CA and
KRAS mutations (P = 0.075), while only one case had
PIK3CA and BRAF mutations. The concomitant occur-
rence of PIK3CA and KRAS mutations was reported
previously in CRC and other human cancer types
[21,35]. The coexistence of KRAS and BRAF mutations
was not observed in our patient cohort, consistent with
earlier studies. The mutual exclusive occurrence of
KRAS and BRAF mutations suggests they occur in dif-
ferent tumor subtypes [12].
We also investigated the clinicopathological characte-
ristics of CRC patients with respect to KRAS, BRAF,
PIK3CA mutations. We found that the frequencies of
BRAF and PIK3CA mutations were significantly lower in
rectal than in colon cancer. A lower frequency in rectal
cancer was also observed in a few Western studies [35].
This observation emphasizes the difference between
colon and rectal cancers, which may result in distinct
treatment responses and prognosis [41,42].
In this Chinese cohort of 126 sporadic colon cancer pa-
tients, we found that the BRAF V600E mutation was sig-
nificantly associated with a higher metastatic rate and a
poorer OS. In the multivariate analysis, BRAF V600E was
an independent prognostic factor for OS in colon cancer,
next to sex and TNM (Table 6). Actually, together with
another case harboring a BRAF K601E mutation, BRAF
mutations was also associated with a poorer OS (log rank,
P = 0.002, data not shown) in our study cohort. It has beenS codon 12 and 13 mutations in 205 BRAF wt colorectal
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
1 1
2.4 (1.1-5.3) 0.026 2.6 (1.2-5.8) 0.016
1.4 (0.6-3.0) 0.425 1.1 (0.5-2.4) 0.853
1.4 (0.5-3.6) 0.546 1.5 (0.6-4.0) 0.408
lected in Table 7. P-values ≤ 0.05 are in bold.
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poor prognosis in Western CRC patients [9,10,12,13].
However, among the limited number of BRAF mutation
studies in Chinese patients, only one study performed a
survival analysis in a sample of 314 patients, including
colon and rectum cancers. Although they reported the
same conclusion as we do, they did not clarify which mu-
tation types contributed to this effect [26]. As our patients
were treated with the same chemotherapy and none of
them received targeted therapy after surgery, our result
may be interpreted as that the BRAF V600E mutation is a
sensitive prognostic indicator independent of treatment
regimen and disease progression. Obviously, this observa-
tion needs to be confirmed in a larger population of
Chinese patients. Nevertheless, our findings suggest that
prospective evaluation of the BRAF mutation status is
equally important in Chinese patients with colon cancer,
even though its mutation frequency (4-7%) is lower than
Western patients and no effective therapy available. The
manifest adverse effects of this mutation require more
vigorous treatment and surveillance in this group of high-
risk patients.
Another point worth noting was that sex was an inde-
pendent predictor for prognosis in our colon cancer pa-
tients, with male patients being at a higher risk than
female patients. Concordant with our conclusion, the
study [43] which looked at the cumulative 10-year inci-
dence and mortality of CRC among men at ages 50, 55,
and 60 in US revealed that women reached equivalent
levels of disease 4–8 years later than men. This finding
indicates the importance in the choice of age at initi-
ation of CRC screening.
Although, the predictive role of KRAS mutation in
adopting anti-EGFR antibody therapy has been well re-
cognized, its prognostic value in survival remains contro-
versial. This may be caused by different study size,
patient selection, operation options, chemotherapy regi-
mens, sample controlling, material characters, detection
method and data analysis. Importantly, few studies
realized that KRAS wt samples were mixed with BRAF
mutants, which strongly affects the prognostic value of
KRAS mutations [13,14]. In our study, the negative prog-
nostic role of KRAS mutations emerged when BRAF mu-
tant patients were separated from the KRAS wt patients
(Figure 3C).
Only a small and very recent detailed analysis esti-
mated the prognostic effect of KRAS mutations when
codon 12 and 13 are counted separately [13,14,20]. The
main finding of these clinical studies is that KRAS muta-
tions in codon 13 confer a poorer prognosis and outcome
on patients under standard chemotherapy. In agreement,
our KM curves clearly demonstrated that OS in patients
with KRAS codon 13 mutations, in particular, c.38G > A
(p.G13D, the most frequent codon 13 mutation in ourpatients (23 out of 25) and in general [19]), was signifi-
cantly worse than that in patients without KRAS and
BRAF mutations (Figure 3D&E). KRAS codon 12 muta-
tions, on the other hand, had no effect on patients’ OS in
our study. In both univariate and multivariate analysis,
we further confirmed KRAS codon 13 (G13D) mutation
as an independent negative prognostic factor for OS.
Since our patients had only received standard chemo-
therapy and none of them had targeted medicine after
resection, our findings support KRAS codon 13 (G13D)
mutation as a prognostic biomarker in the natural
process of colorectal cancer.
In contrast to the clinical findings, the in vitro studies
suggested that KRAS codon 13 (G13D) mutations confer
a weaker transforming capacity on cells than codon 12
mutations [20]. In addition, recent computational ana-
lysis revealed that KRAS protein with a mutation in
codon 13 has a similar structure and dynamics as KRAS
wt protein. Consequently, patients with this mutation
could benefit from anti-EGFR antibody therapy [44]. In
fact, several recent studies investigated the efficacy of
anti-EGFR therapies for mutations in codon 13 and 12
separately [20] and reported improved PFS and OS for
advanced CRC patients with the G13D mutation after
receiving cetuximab alone or in combination with
chemotherapy. Therefore, KRAS codon (G13D) may not
only be a prognostic biomarker but may also be predict-
ive for a positive response to anti-EGFR treatment.
The limitations of this study include its retrospective
nature, relatively small sample size (n = 214) and short
follow-up time. Nevertheless, we have found that BRAF
V600E and KRAS G13D mutations were associated with
worse OS in Chinese CRC patients. Moreover, we did not
obtain epigenetic status or microsatellite instability (MSI)
data, which plays a role in CRCs. However, the frequency
of BRAF mutation is low in Chinese CRC patients, with
only 9 (~4%) in the present study, so that further sub-
group analysis was not feasible in this study. We are en-
larging our sample size by recruiting CRC patients from
other clinical centers and will have longer follow-up data
for further analysis. Furthermore, additional mutations,
including KRAS mutations beyond exon 2 and NRAS
mutations, will be analyzed in our cohorts, since current
studies based on Western CRC patients seem to suggest
that they may be prognostic for outcome and predictive
for the efficacy of anti-EGFR therapies [45], and few data
is available on Chinese patients.
Conclusion
In conclusion, our study demonstrated the BRAF V600E
mutation was an independent prognostic factor for colon
cancer patients and was the first study on Chinese
patients to find that KRAS codon 13 mutations (in par-
ticular, c.38G > A, p.G13D), but not codon 12 mutations,
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CRCs. A single mutation type may represent a distinct
biologic effect and clinical implication [46], but also ap-
pears to convey benefit from a targeted therapy. Our
findings show that molecular features in CRC patients
are important to avoid confounding effects in future clin-
ical trials.
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